Celularity
Celularity develops off-the-shelf placental-derived allogeneic cell therapies and biomaterials targeting cancer, immunologic, infectious, and degenerative diseases, with a state-of-the-art facility and a diverse clinical pipeline.
Overview of Celularity
Founded in 2017 as a spin-out from Celgene, Celularity is a biotechnology company focused on developing off-the-shelf placental-derived allogeneic cell therapies. The company's pipeline includes both genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs). Celularity targets various indications such as cancer, immunologic, infectious, and degenerative diseases. In 2021, Celularity became a public company.
Cell Therapy Products
Celularity develops multiple cell therapy candidates, including CYNK-001, the only cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell therapy derived from placental hematopoietic stem cells. The company also develops CYNK-101, genetically-modified NK cells for combination treatment with antibody-based anti-cancer treatments, and CYNK-CAR, natural killer chimeric antigen receptor cells for hematological and solid tumor targets. These products are currently in active clinical development.
Placental-Derived Biomaterials
Celularity offers a range of placental-derived biomaterial products aimed at therapeutic use. These include products like Biovance®, Biovance® 3L, Interfyl®, and CentaFlex® for soft tissue repair and reconstructive procedures. The company is also developing novel products such as Celularity Tendon Wrap, Celularity Bone Void Filler, and Celularity Placental Matrix, as well as advanced biomaterial products like human amniotic membrane allografts and decellularized human placental connective tissue matrices.
Innovative Manufacturing Facility
Celularity operates a state-of-the-art, purpose-built facility equipped with 150,000 sq ft of laboratory and advanced manufacturing space for cellular medicine and biomaterials. The facility includes nine Grade C/ISO 7 suites and six Grade D/ISO 8 labs, all of which are GMP-capable. The facility is staffed by over 100 highly specialized scientists, engineers, and technicians. This infrastructure supports the company's broad range of activities in cell therapy and biomaterials development.
Strategic Collaborations
Celularity collaborates with several notable companies in the biotechnology field. The company's partnerships include collaborations with Imugene, Oncternal Therapeutics, and Palantir Technologies. These collaborations aim to advance Celularity's mission of developing innovative cellular therapies and biomaterials derived from the postpartum placenta.